Trial Profile
Phase II clinical trial with tri-weekly metronomic oral vinorelbine and cisplatin as induction treatment for and subsequent concomitant with radiotherapy (RT) in patients with non small cell lung cancer (NSCLC) locally advanced unresectable
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Vinorelbine (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NORA
- 08 Jan 2020 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 First efficacy results (n=57) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 27 Apr 2018 Status changed from recruiting to active, no longer recruiting.